Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G Lebwohl

Showing results (191-200 of 209) with videos related to

Pageof 21
Sort By:
Allergy|October 22, 2022
Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areataYael Renert-Yuval, Ana B Pavel, Ester Del Duca, et al.
The New England Journal of Medicine|December 22, 2021
Trial of Spesolimab for Generalized Pustular PsoriasisHervé Bachelez, Siew-Eng Choon, Slaheddine Marrakchi, et al.
Advances in Therapy|July 12, 2025
Correction to: Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability StudyMark G Lebwohl, John Y Koo, Janusz Jaworski, et al.
Advances in Therapy|February 11, 2025
Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability StudyMark G Lebwohl, John Y Koo, Janusz Jaworski, et al.
Journal of the American Academy of Dermatology|August 20, 2021
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trialAndrew Blauvelt, Jonathan I Silverberg, Charles W Lynde, et al.
Journal of the American Academy of Dermatology|November 19, 2025
Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitorsAndrew Blauvelt, Bruce E Strober, Guy S Eakin, et al.
The New England Journal of Medicine|December 8, 2021
Phase 3 Trials of Tapinarof Cream for Plaque PsoriasisMark G Lebwohl, Linda Stein Gold, Bruce Strober, et al.
The British Journal of Dermatology|August 28, 2025
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site InvolvementLinda Stein Gold, Alice B Gottlieb, April W Armstrong, et al.
Dermatology and Therapy|October 24, 2025
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III TrialsKim A Papp, James Q Del Rosso, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology|July 16, 2016
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adultsAmy S Paller, Wynnis L Tom, Mark G Lebwohl, et al.
Pageof 21

Showing results (191-200 of 209) with videos related to

Sort By:
Pageof 21
Allergy|October 22, 2022
Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areataYael Renert-Yuval, Ana B Pavel, Ester Del Duca, et al.
The New England Journal of Medicine|December 22, 2021
Trial of Spesolimab for Generalized Pustular PsoriasisHervé Bachelez, Siew-Eng Choon, Slaheddine Marrakchi, et al.
Advances in Therapy|July 12, 2025
Correction to: Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability StudyMark G Lebwohl, John Y Koo, Janusz Jaworski, et al.
Advances in Therapy|February 11, 2025
Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability StudyMark G Lebwohl, John Y Koo, Janusz Jaworski, et al.
Journal of the American Academy of Dermatology|August 20, 2021
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trialAndrew Blauvelt, Jonathan I Silverberg, Charles W Lynde, et al.
Journal of the American Academy of Dermatology|November 19, 2025
Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitorsAndrew Blauvelt, Bruce E Strober, Guy S Eakin, et al.
The New England Journal of Medicine|December 8, 2021
Phase 3 Trials of Tapinarof Cream for Plaque PsoriasisMark G Lebwohl, Linda Stein Gold, Bruce Strober, et al.
The British Journal of Dermatology|August 28, 2025
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site InvolvementLinda Stein Gold, Alice B Gottlieb, April W Armstrong, et al.
Dermatology and Therapy|October 24, 2025
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III TrialsKim A Papp, James Q Del Rosso, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology|July 16, 2016
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adultsAmy S Paller, Wynnis L Tom, Mark G Lebwohl, et al.
Pageof 21